|
STAT3 |
signal transducer and activator of transcription 3 |
- Interleukin-6 signaling
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- Signalling to STAT3
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by Leptin
- POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
- Association of TriC/CCT with target proteins during biosynthesis
- Transcriptional regulation of pluripotent stem cells
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- PTK6 Activates STAT3
- PTK6 Activates STAT3
- Interleukin-20 family signaling
- MET activates STAT3
- MET activates STAT3
- Interleukin-15 signaling
- Interleukin-35 Signalling
- Interleukin-9 signaling
- Interleukin-37 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-21 signaling
- Transcriptional regulation of granulopoiesis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Growth hormone receptor signaling
|
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
- Oral cancer
|
|
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by ERBB2
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D induced cell migration and growth-cone collapse
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
- Trastuzumab
- Lapatinib
- IGN311
- Trastuzumab emtansine
- Varlitinib
- AV-412
- Pertuzumab
- Afatinib
- Tucatinib
- Tesevatinib
- Fostamatinib
- Brigatinib
- Margetuximab
- Zanubrutinib
|
- Choriocarcinoma
- Pancreatic cancer
- Gastric cancer
- Bladder cancer
- Endometrial Cancer
- Ovarian cancer
- Cholangiocarcinoma
- Breast cancer
- Cervical cancer
|
|
SHC1 |
SHC adaptor protein 1 |
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signalling to RAS
- SHC1 events in EGFR signaling
- Tie2 Signaling
- Integrin signaling
- XBP1(S) activates chaperone genes
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- RET signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
|
|
|
CTNNB1 |
catenin beta 1 |
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- TCF dependent signaling in response to WNT
- Formation of the beta-catenin:TCF transactivating complex
- Formation of the beta-catenin:TCF transactivating complex
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Apoptotic cleavage of cell adhesion proteins
- Deactivation of the beta-catenin transactivating complex
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
- Ca2+ pathway
- Adherens junctions interactions
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- VEGFR2 mediated vascular permeability
- Myogenesis
- Myogenesis
- Signaling by GSK3beta mutants
- S33 mutants of beta-catenin aren't phosphorylated
- S37 mutants of beta-catenin aren't phosphorylated
- S45 mutants of beta-catenin aren't phosphorylated
- T41 mutants of beta-catenin aren't phosphorylated
- RHO GTPases activate IQGAPs
- Transcriptional Regulation by VENTX
- InlA-mediated entry of Listeria monocytogenes into host cells
- RUNX3 regulates WNT signaling
|
|
- Gastric cancer
- Colorectal cancer
- Endometrial Cancer
- Pilomatricoma; Epithelioma calcificans of Malherbe
- Thyroid cancer
- Hepatocellular carcinoma
|
|
GAB1 |
GRB2 associated binding protein 1 |
- PI3K Cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PIP3 activates AKT signaling
- GAB1 signalosome
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- Signaling by FGFR3 fusions in cancer
- Signaling by FGFR3 point mutants in cancer
- RET signaling
- MET activates PTPN11
- MET activates RAP1 and RAC1
- MET receptor recycling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
|
|
|
|
SYK |
spleen associated tyrosine kinase |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- FCGR activation
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Role of phospholipids in phagocytosis
- DAP12 signaling
- Fc epsilon receptor (FCERI) signaling
- Fc epsilon receptor (FCERI) signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Integrin signaling
- CLEC7A (Dectin-1) signaling
- Dectin-2 family
- Dectin-2 family
- Interleukin-2 signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- FLT3 signaling through SRC family kinases
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Staurosporine
- N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
- Tamatinib
- 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
- 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
- Ellagic acid
- Fostamatinib
|
|
|
VAV1 |
vav guanine nucleotide exchange factor 1 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- NRAGE signals death through JNK
- Rho GTPase cycle
- Regulation of actin dynamics for phagocytic cup formation
- Constitutive Signaling by Aberrant PI3K in Cancer
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- CD28 dependent Vav1 pathway
- G alpha (12/13) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- VEGFR2 mediated vascular permeability
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Regulation of signaling by CBL
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
|
LCK |
LCK proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Nef Mediated CD4 Down-regulation
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- CTLA4 inhibitory signaling
- PD-1 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Interleukin-2 signaling
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- FLT3 signaling through SRC family kinases
|
- Dasatinib
- AP-22408
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
- Nintedanib
- Fostamatinib
- Zanubrutinib
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|
|
ITGB1 |
integrin subunit beta 1 |
- Elastic fibre formation
- Fibronectin matrix formation
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Cell surface interactions at the vascular wall
- Basigin interactions
- Molecules associated with elastic fibres
- Integrin cell surface interactions
- Integrin cell surface interactions
- Laminin interactions
- Laminin interactions
- Syndecan interactions
- ECM proteoglycans
- Other semaphorin interactions
- Signal transduction by L1
- Localization of the PINCH-ILK-PARVIN complex to focal adhesions
- CHL1 interactions
- RHO GTPases Activate Formins
- Interleukin-4 and Interleukin-13 signaling
- Platelet Adhesion to exposed collagen
- MET activates PTK2 signaling
- MET interacts with TNS proteins
- HCMV Early Events
- Potential therapeutics for SARS
|
- Antithymocyte immunoglobulin (rabbit)
- MK-0668
|
|
|
CBL |
Cbl proto-oncogene |
- Interleukin-6 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Spry regulation of FGF signaling
- Regulation of KIT signaling
- EGFR downregulation
- TGF-beta receptor signaling activates SMADs
- Constitutive Signaling by EGFRvIII
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Negative regulation of MET activity
- PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- InlB-mediated entry of Listeria monocytogenes into host cell
- InlB-mediated entry of Listeria monocytogenes into host cell
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Negative regulation of FLT3
- FLT3 signaling by CBL mutants
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
YES1 |
YES proto-oncogene 1, Src family tyrosine kinase |
- Signaling by ERBB2
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- FCGR activation
- PECAM1 interactions
- EPH-Ephrin signaling
- CD28 co-stimulation
- CTLA4 inhibitory signaling
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- RUNX2 regulates osteoblast differentiation
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
|
|
|
|
CDK4 |
cyclin dependent kinase 4 |
- SCF(Skp2)-mediated degradation of p27/p21
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- RMTs methylate histone arginines
- Transcriptional regulation of white adipocyte differentiation
- Cyclin D associated events in G1
- Ubiquitin-dependent degradation of Cyclin D
- Ubiquitin-dependent degradation of Cyclin D
- PTK6 Regulates Cell Cycle
- Transcriptional regulation by RUNX2
- Meiotic recombination
- Transcriptional regulation of granulopoiesis
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
|
- Purvalanol
- Alvocidib
- Palbociclib
- Ribociclib
- Abemaciclib
- Fostamatinib
|
- Glioma
- Malignant melanoma
- Cervical cancer
|
|
PIK3R3 |
phosphoinositide-3-kinase regulatory subunit 3 |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- Constitutive Signaling by Aberrant PI3K in Cancer
- Costimulation by the CD28 family
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- Extra-nuclear estrogen signaling
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
|
|
|
|
HGF |
hepatocyte growth factor |
- Platelet degranulation
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- MET Receptor Activation
- Negative regulation of MET activity
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates RAS signaling
- MET activates PI3K/AKT signaling
- MET activates PTPN11
- MET activates PTK2 signaling
- MET interacts with TNS proteins
- MET activates RAP1 and RAC1
- MET receptor recycling
- MET activates STAT3
|
- Heparin
- O2-Sulfo-Glucuronic Acid
- N,O6-Disulfo-Glucosamine
- ABT-510
- Foretinib
|
|
|
PLCG2 |
phospholipase C gamma 2 |
- GPVI-mediated activation cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Synthesis of IP3 and IP4 in the cytosol
- Generation of second messenger molecules
- Role of phospholipids in phagocytosis
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- CLEC7A (Dectin-1) signaling
- CLEC7A (Dectin-1) signaling
- Dectin-2 family
- Dectin-2 family
- Erythropoietin activates Phospholipase C gamma (PLCG)
- FCGR3A-mediated IL10 synthesis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
|
VAV2 |
vav guanine nucleotide exchange factor 2 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- NRAGE signals death through JNK
- Rho GTPase cycle
- Regulation of actin dynamics for phagocytic cup formation
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- EPH-ephrin mediated repulsion of cells
- G alpha (12/13) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Signal transduction by L1
- VEGFR2 mediated vascular permeability
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
|
|
|
|
VAV3 |
vav guanine nucleotide exchange factor 3 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- NRAGE signals death through JNK
- Rho GTPase cycle
- Regulation of actin dynamics for phagocytic cup formation
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- EPH-ephrin mediated repulsion of cells
- G alpha (12/13) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated vascular permeability
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
|
|
|
|
BTK |
Bruton tyrosine kinase |
- ER-Phagosome pathway
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- Regulation of actin dynamics for phagocytic cup formation
- DAP12 signaling
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- G alpha (q) signalling events
- G alpha (12/13) signalling events
- MyD88 deficiency (TLR2/4)
- IRAK4 deficiency (TLR2/4)
- RHO GTPases Activate WASPs and WAVEs
- G beta:gamma signalling through BTK
- FCGR3A-mediated phagocytosis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Dasatinib
- Inositol 1,3,4,5-Tetrakisphosphate
- XL418
- Ibrutinib
- Acalabrutinib
- Fostamatinib
- Zanubrutinib
- Abivertinib
|
- Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
- Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
|
|
CASP3 |
caspase 3 |
- Activation of caspases through apoptosome-mediated cleavage
- SMAC (DIABLO) binds to IAPs
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- Apoptotic cleavage of cellular proteins
- SMAC, XIAP-regulated apoptotic response
- Apoptosis induced DNA fragmentation
- Degradation of the extracellular matrix
- Signaling by Hippo
- NADE modulates death signalling
- Stimulation of the cell death response by PAK-2p34
- Caspase-mediated cleavage of cytoskeletal proteins
- Apoptotic cleavage of cell adhesion proteins
- Caspase activation via Dependence Receptors in the absence of ligand
- Caspase activation via Dependence Receptors in the absence of ligand
- Other interleukin signaling
|
- Pamidronic acid
- Acetylsalicylic acid
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- Emricasan
- Incadronic acid
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
- Glycyrrhizic acid
|
|
|
MYC |
MYC proto-oncogene, bHLH transcription factor |
- Transcription of E2F targets under negative control by DREAM complex
- NOTCH1 Intracellular Domain Regulates Transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- MAPK6/MAPK4 signaling
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- RUNX3 regulates WNT signaling
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
|
- Acetylsalicylic acid
- Nadroparin
|
- Choriocarcinoma
- Penile cancer
- Burkitt lymphoma
- Oral cancer
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Multiple myeloma
- Small cell lung cancer
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
- Osteosarcoma
- Kaposi's sarcoma
- Laryngeal cancer
- Breast cancer
- Ovarian cancer
|